FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to methods of treating diseases accompanied by the deposition of amyloid, in particular primary amyloidosis, to a method for detecting the presence of amyloid deposits of primary amyloidosis, to a method of reducing the amount of deposits of fibrillar aggregates formed by light chains of the kappa and / or lambda type in a patient with a diagnosis of primary amyloidosis; and a method for treating amyloid light-chain amyloidosis (ALA) with heart disease in a patient where ALA does not achieve hematologic remission by the use of a chimeric (mouse and human) antibody to amyloid fibrils.
EFFECT: invention provides an effective treatment of diseases associated with amyloid deposition, in particular primary amyloidosis.
30 cl, 14 dwg, 13 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIBODIES FOR TREATMENT OF DISEASES CHARACTERIZED BY AMYLOIDE DEPOSITION | 2018 |
|
RU2746325C1 |
| PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY | 2008 |
|
RU2523894C2 |
| HUMANISED ANTIBODY | 2008 |
|
RU2538709C2 |
| APPLICATION OF ANTIBODY AGAINST AMYLOID-BETA IN CASE OF EYE DISEASES | 2008 |
|
RU2571859C2 |
| FUSED MOLECULE CAPABLE OF INDUCING NON-INFLAMMATORY PHAGOCYTOSIS | 2022 |
|
RU2823919C1 |
| HUMANISED ANTIBODY TO BETA AMYLOID | 2007 |
|
RU2498999C2 |
| HUMANISED ANTIBODIES TO AMYLOID BETA | 2008 |
|
RU2567151C2 |
| HUMANIZED ANTIBODY TO BETA AMYLOID | 2013 |
|
RU2668161C2 |
| USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2542967C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
